Shares of Aeterna Zentaris (AEZS +13.2%) pop after being initiated with a Buy at Roth Capital...
Shares of Aeterna Zentaris (AEZS +13.2%) pop after being initiated with a Buy at Roth Capital with a price target of $1.75, more than double its current valuation. Roth cites optimism over its endometrial cancer candidate, AEZS-108, which plans to begin Phase III testing before the end of the year, the potential for its AEZS-130, an Adult Growth Hormone Deficiency diagnostic that the company is preparing for a New Drug Application.
From other sites
at Zacks.com (Apr 29, 2015)
at Zacks.com (Mar 23, 2015)
at CNBC.com (Nov 6, 2014)
at CNBC.com (Jan 9, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs